Renalytix Plc Regulatory News (RENX)

Renalytix plc

("Renalytix" or the "Company")

Directorate Change

Julian Baines MBE appointed as Executive Chairman

LONDON and NEW YORK, 5 November 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the appointment of Julian Baines MBE as Executive Chairman after shareholders approved the resolution passed at the Company's General Meeting on 31 October 2024. Julian replaces Christopher Mills who will move to a Non-Executive Director role.

Julian has significant experience in the life science industry and was the CEO of EKF Diagnostics Holdings Plc ("EKF") and BBI Holdings plc. Julian rejoined the executive team at EKF as Executive Chairman in February 2023. Julian is also currently Non-Executive Chairman of Verici Dx plc. Before joining EKF, he undertook a management buyout at BBI in 2000, a flotation on AIM in 2004 and was responsible for selling the business to Alere Inc. (now part of Abbott Laboratories) in 2008 for c. £85 million. Julian was previously Non-Executive Chairman of Renalytix from March 2018 to June 2020.

Julian Baines MBE

Executive Chairman of Renalytix PLC

James McCullough, CEO of Renalytix plc, commented: "I am delighted to welcome Julian back to the Board of Renalytix. Julian has a wealth of knowledge in the sector and significant experience with AIM listed healthcare companies which will be paramount toward supporting the commercial success of our business. Most importantly, I would like to thank Christopher for his continuing contribution to Renalytix. It is a pleasure to work alongside him, and his leadership as Chairman has been invaluable."

Additional Disclosures Required under the AIM Rules for Companies

Julian Huw Baines (aged 60) has held the following directorship or partnerships in the past five years:

Julian Baines was a director of BB Electronics Limited, which went into liquidation in 1991 with a creditor shortfall of approximately £400,000. He was also a director of Calibre Communications Limited, which went into liquidation in 1991 with a creditor shortfall of approximately £20,000. Julian Baines was not the subject of public criticism by the liquidator in connection with the liquidations.

Julian Baines and persons closely associated (as defined under MAR) with Mr Baines currently hold 1,801,711 ordinary shares of £0.0025 each in the Company.

Save as disclosed above, there is no further information to be disclosed in respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for Companies.

For further information, please contact:

About Renalytix

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com